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I. INTRODUCTION
[1]
Genes are the fundamental building blocks of all living things.
They dictate hair color, eye color, even susceptibility to cancer. 1 As such,
genes inherently possess untold power. The ability of a sole company to

* J.D. Candidate 2013, University of Richmond School of Law. I would like to thank
Professor Kristen Osenga for her helpful comments and insight in publishing this
comment.
1

See Patrick Sulem et al., Genetic determinants of hair, eye and skin pigmentation in
Europeans, 39 NATURE GENETICS 1443, 1444, 1446, 1448 (2007); Richard Wooster et
al., Localization of a Breast Cancer Susceptibility Gene, BRCA2, to Chromosome 13q1213, 265 SCI. 2088, 2089 (1994).
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wield this omnipotence makes a human gene patent highly sought after. 2
Notwithstanding the other requirements for patentability, the eligibility of
human genes as ‘inventions’ worthy of patent protection under 35 U.S.C.
§ 101 has recently been called into question. In Association for Molecular
Pathology v. U.S. Patent and Trademark Office (“the Myriad decision”),
the Federal Circuit answered in the affirmative. 3 In arriving at this
conclusion, the majority rejected the biological significance of the
information contained in the deoxyribonucleic acid (“DNA”) molecule in
favor of a purely structural approach. 4 The court incorrectly concluded
that an isolated DNA molecule is “markedly different” from native DNA
because of minor structural differences. 5 The court discounted the fact
that both the isolated DNA and the relevant portion of the native DNA
contain the same sequence of nucleotides and therefore the same
biological information. 6 While the Federal Circuit incorrectly considered
this issue by narrowly looking at DNA structure, there is an alternative
comprehensive approach that considers both important properties of DNA.
This comment proposes a totality-of-the-circumstances approach to
analyzing biological molecules under § 101 such that both the structure
2

Gene patents have broad implications in both the scientific and medical communities;
they permit the monopolization of scientific research and genetic testing on that specific
gene. See generally SECRETARY’S ADVISORY COMM. ON GENETICS, HEALTH, AND
SOC’Y, DEP’T OF HEALTH & HUMAN SERVS., GENE PATENTS AND LICENSING PRACTICES
AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS 28-31 (2010), available at
http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_patents_report_2010.pdf; Mildred
K. Cho et al., Effects of Patents and Licenses on the Provision of Clinical Genetic Testing
Services, 5 J. MOLECULAR DIAGNOSTICS 3, 5-7 (2003).
3

(Myriad II) 653 F.3d 1329, 1334 (Fed. Cir. 2011).

4

Id. at 1352-53.

5

See id. at 1353.

6

See id.
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and its information is examined. Part II of this note reviews relevant
precedent in patent law. Part III analyzes the Federal Circuit’s Myriad
decision, and Part IV explains the potential effects of the recent Supreme
Court decision Mayo Collaborative Services v. Prometheus Laboratories.
Finally, in Part V, the patent eligibility of human genes is examined.
Analyzing this issue under the proposed totality-of-the-circumstances
approach, this article concludes that isolated human genes are not
patentable.
II. GENE PATENT PRECEDENT
[2]
In order to obtain a patent, an invention must comply with Title 35
requirements for patentability. 7 Subject matter eligible for patent
protection is defined in § 101the invention must be a “new and useful
process, machine, manufacture, or composition of matter, or any new and
useful improvement thereof.” 8 When enacting this statute, Congress
intended it be interpreted broadly in order to cover “anything under the
sun made by man.” 9 While incredibly broad, the Court has recognized
three main limitations: an inventor cannot patent the laws of nature,
physical phenomena, or abstract ideas. 10 “The concepts covered by these
exceptions are ‘part of the storehouse of knowledge of all men . . . free to
all men and reserved exclusively to none.’” 11

7

35 U.S.C. § 101 (2006).

8

Id.

9

S. REP. NO. 82-1979, at 5 (1952).

10

Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).

11

Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010) (quoting Funk Bros. Seed Co. v. Kalo
Inoculant Co., 333 U.S. 127, 130 (1948)).

3
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[3]
Interpreting these exceptions, the Court in Diamond v.
Chakrabarty was faced with the issue of whether a human-made,
genetically engineered bacterium was patentable subject matter. 12 The
Court extended the prohibition on the patenting of the laws of nature to
include the products of nature. 13 To be patentable, the invention must be a
product of human ingenuity; it must be “markedly different” from what
exists in nature, “having a distinctive name, character, [and] use.” 14 Thus,
the Court concluded that by adding two oil-degrading plasmids
Chakrabarty had created a new bacterium sufficiently different from that
occurring in nature. 15
[4]
In enunciating its “markedly different” standard, the Chakrabarty
Court adopted the standard promulgated in Hartranft v. Wiegmann. 16 The
issue in Hartranft was whether a polished seashell was an article of
manufacture. 17 After harvesting, raw seashells were acid etched, ground
to expose their interior layer, and then polished. 18 The Court held that
even though the shells had undergone changes, they still had the same
“name, character, [and] use” as a shell picked up off the ground. 19 Thus,
12

447 U.S. at 305.

13

Id. at 313; see also H.R. REP. NO. 1129, at 7 (1930); S. REP. NO. 315, at 6 (1930).

14

Diamond, 447 U.S. at 309-10 (quoting Hartranft v. Wiegmann, 121 U.S. 609, 615
(1887)).

15

Id. at 310.

16

Id. at 309-10 (citing Hartranft, 121 U.S. at 609).

17

Hartranft, 121 U.S. at 613.

18

Id. at 611.

19

Id. at 615.
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the polished shells were not transformed into a different article of
manufacture. 20
[5]
The seashells in Hartranft are similar to the inoculant created in
Funk Brothers Seed Co. v. Kalo Inoculant. 21 In Funk Brothers, the Court
sought to determine the validity of a patent for an inoculant containing
several species of bacteria that were not mutually inhibiting. 22 As the
bacteria in the inoculant were identical to the bacteria as they existed in
nature, the patent claimed the naturally occurring properties of the
bacteria; the fact that when combined they do not inhibit the desirable
properties of each other. 23 Thus, the invention was held not patentable
subject matter as it sought to claim the laws of nature. 24 In the shadow of
this precedent, the Federal Circuit took it upon themselves to decide the
issue of whether human genes are patentable subject matter.
III. THE MYRIAD DECISION
[6]
The controversy began in 2009 when Association for Molecular
Pathology25 filed a declaratory judgment action against Myriad Genetics,
20

Id.

21

See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948).

22

Id. at 128.

23

Id. at 131.

24

Id. at 132.

25

Association for Molecular Pathology was the first named party in the case. Other
plaintiffs include the American College of Medical Genetics, the American Society for
Clinical Pathology, Breast Cancer Action, Boston Women’s Health Book Collective,
eight doctors, and six women seeking breast cancer genetic testing. Ass’n for Molecular
Pathology v. U.S. Patent & Trademark Office (Myriad I), 702 F. Supp. 2d 181, 186-89
(S.D.N.Y. 2010).

5
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the University of Utah Research Foundation, and the U.S. Patent and
Trademark Office (collectively “Myriad”) alleging fifteen claims,
spanning seven patents, were invalid as unpatentable subject matter. 26
The patents at issue covered segments of “isolated DNA” and cDNA 27
from the BRCA1 and BRCA2 genes as well as methods for “analyzing” or
“comparing” segments of isolated DNA to determine the presence of
mutations. 28 The BRCA1 and BRCA2 genes encode proteins integral in
the repair of DNA breaks. 29 Certain mutations in these genes have been
observed to correlate to one’s susceptibility to breast and ovarian cancer. 30
[7]
Recognizing the case’s significance, the district court concisely
stated the issue: “[a]re isolated human genes . . . patentable?” 31 The
district court held human genes not patentable under § 101 because “DNA
represents the physical embodiment of biological information” and thus
falls under the law of nature exception to § 101.32 Myriad appealed to the
Federal Circuit. 33
26

Id. at 184 (challenging the validity of claims 1, 2, 5, 7, and 20 of U.S. Patent 5,747,282,
claims 1, 6, and 7 of U.S. Patent 5,837,492, claim 1 of U.S. Patent 5,693,472, claim 1 of
U.S. Patent 5,709,999, claim 1 of U.S. Patent 5,710,001, claim 1 of U.S. Patent
5,753,441, and claims 1 and 2 of U.S. Patent 6,033,857).
27

Isolated DNA is a nucleotide segment removed from the chromosome and separated
from the extraneous cellular components. See infra Part V.D. cDNA is a piece of
artificially created DNA. Id.
28

Myriad II, 653 F.3d 1329, 1334-35 (Fed. Cir. 2011).

29

Kiyotsugu Yoshida & Yoshio Miki, Role of BRCA1 and BRCA2 as regulators of DNA
repair, transcription, and cell cycle in response to DNA damage, 95 CANCER SCI., 866,
866-68 (2004).
30

Myriad II, 653 F.3d at 1339; see also Wooster, supra note 1, at 2089.

31

Myriad I, 702 F. Supp. 2d at 185.

32

Id.

33

Myriad II, 653 F.3d at 1333.
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A. Federal Circuit: Judge Lourie’s Majority Opinion
[8]
In his opinion Judge Lourie characterizes three types of DNA:
native DNA, isolated DNA, and cDNA. 34 Native DNA is the single DNA
molecule that composes each chromosome. 35 Native DNA, as the name
suggests, is the form of DNA exactly as found in nature. 36 It contains both
coding exon and non-coding intron regions of many genes. 37 It is found
covalently bonded to a complementary strand of DNA and wound around
histones, proteins which “package” or condense the DNA into
chromatin. 38 Isolated DNA, on the other hand, is native DNA in which
the histones have been removed and a sequence, containing an entire gene,
has been cut out of the chromosomal structure. 39 Finally, cDNA is a form
of synthetic DNA, made by humans in a laboratory, containing only
protein coding regions of DNA. 40
[9]
Examining the patent eligibility of each of these types of DNA,
Judge Lourie quickly decided the fates of genomic DNA and cDNA. He
correctly distinguished native DNA as existing in nature, thus preventing
34

Id. at 1351-53.

35

Id. at 1351.

36

Id.

37

Id. at 1339.

38

Myriad II, 653 F.3d at 1338 fig.4.

39

Id. at 1351-52. Judge Lourie also incorrectly lumps isolated cDNA with isolated
genomic DNA. When considering isolated DNA, isolated cDNA should not be
considered along with isolated genomic DNA. Isolated cDNA is simply a shortened form
of cDNA, and therefore should be analyzed as cDNA for the purposes of § 101.

40

Id. at 1338-39.

7
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patenting. 41 As native DNA is devoid of any human innovation or
modification, it is not patent-eligible subject matter under § 101. 42 Judge
Lourie also correctly found cDNA to be patentable subject matter. 43 The
creation of cDNA requires extensive human intervention and
modification; it is quintessentially man-made. 44 Therefore, Judge Lourie
held it should be afforded patent protection under § 101. 45
[10] On the other hand, determining the patent eligibilty of isolated
genomic DNA sequences required a more intricate analysis. Examining
isolated DNA, Judge Lourie compares it to its native counterpart from a
chemical, as opposed to a biological, perspective. 46 From a chemical
perspective, the differences in DNA structure were compared, not the
differences in information content characteristic of a biological
perspective. 47 Looking at the structure of the chromosomal DNA, Judge
Lourie noted the chromosomes containing the BRCA1 and BRCA2 genes
are approximately eighty million and one hundred fourteen million
nucleotides in length, respectively. 48 Yet, the actual genes are merely
fragments of the astronomically large strands of DNA comprising each

41

See id. at 1351.

42

See id.

43

See Myriad II, 653 F.3d at 1350.

44

See id. at 1338-39.

45

Id. at 1350.

46

Id. at 1351-53.

47

Id.

48

Myriad II, 653 F.3d at 1351-52.
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chromosome. 49 When the BRCA1 and BRCA2 genes are removed in the
creation of isolated DNAs, each are approximately 7,000 and 11,000 base
pairs in length, respectively. 50 Judge Lourie states this extensive
modification of the chemical structure of the genomic DNA makes
isolated DNA’s structure markedly different from that of native DNA. 51
And for purposes of patentability, it is the change in physical structure of
the molecule, not the information that is conveyed, that is the proper gauge
for determining the differences from native form. 52 Therefore, Judge
Lourie concluded that the chemical bonds broken in the creation of
isolated DNA are sufficient structural changes to warrant patent
eligibility. 53
B. Federal Circuit: Judge Moore’s Concurrence-In-Part
[11] Arriving at the same conclusion as the majority, Judge Moore
applied a slightly different, more skeptical, analysis of the science. As an
initial matter, Judge Moore agreed that cDNA is patent eligible subject
matter; it is made by man and is not found in nature. 54 Next, she
49

BRCA2 is one of 720 genes composing the 115M bp of chromosome 13, and BRCA1
is just one of the 1773 genes on the 81M bp chromosome 17. NCBI Map Viewer,
Chromosome
13,
NAT’L
CENTER
FOR
BIOTECHNOLOGY
INFO.,
http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?ORG=hum&MAPS=ideogr,est,loc&LI
NKS=ON&VERBOSE=ON&CHR=13 (last visited Mar. 19, 2012); NCBI Map Viewer,
Chromosome
17,
NAT’L
CENTER
FOR
BIOTECHNOLOGY
INFO.,
http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?ORG=hum&MAPS=ideogr,est,loc&LI
NKS=ON&VERBOSE=ON&CHR=17 (last visited Mar. 19, 2012).
50

Myriad II, 653 F.3d at 1351-52.

51

Id. at 1352.

52

Id. at 1353.

53

Id. at 1352-53.

54

Id. at 1364 (Moore, J., concurring).
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examined the structural differences between isolated DNA and genomic
DNA. Agreeing with the majority, she found that the removal of a
segment of DNA from the chromosome is a significant modification, 55 but
that modification only satisfies § 101 because the change imparts a whole
new utility upon the isolated DNA molecule that is not present in the
genomic DNA. 56 Judge Moore qualifies this determination as being
heavily influenced by the historical practice and examination guidelines of
the U.S. Patent Office allowing isolated DNA claims. 57 She notes that
without this background, she might have found that an isolated gene is not
patentable subject matter as it “serves the same ends devised by nature.” 58
C. Federal Circuit: Judge Bryson’s Concurrence-In-Part and
Dissent-In-Part
[12] Unlike the majority and concurring opinions, Judge Bryson
concluded isolated DNA is not patentable subject matter as it is “not
materially different from native genes.” 59 Looking at the significance of
the changes undergone in the creation of isolated DNA, he found the
majority and concurrence placed too much emphasis on the breaking of a
chemical bond. 60 Chemical bonds are broken regularly in a vast myriad of
processes: during the cutting and cleaning of diamonds or the isolation of

55

Myriad II, 653 F.3d at 1364-65 (Moore, J., concurring).

56

Id. at 1365.

57

Id. at 1367 (citing Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093-94 (Jan. 5,
2001)).
58

Id. at 1366-67.

59

Id. at 1373-75 (Bryson, J., dissenting).

60

Myriad II, 653 F.3d at 1376.
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the element lithium.61 Even in genetics, the chemical bonds holding the
DNA backbone together are broken and reformed on a regular basis. 62
The routine nature of breaking chemical bonds therefore makes them an
arbitrary method for determining patentability of DNA, especially when
the method has been expressly rejected in the past. 63
[13] Rejecting the chemical approach of looking solely at structure,
Judge Bryson likens the creation of isolated DNA to the snapping of a leaf
from a tree. 64 When a person snaps a leaf from a tree, she breaks chemical
bonds that had previously attached it to the branch. In doing so, she has
imparted new characteristics and uses upon the leaf. It no longer can be
used to convert the sun’s energy into food, as nature would use it. Rather,
it can be used for decoration, consumption, or a myriad of other uses. Yet,
as Judge Bryson notes, even though the leaf was broken from the structure
of the tree by man, and this breaking imparted a new utility not previously
present, the leaf was created by nature, just as the tree was, and is
therefore not patentable. 65 Isolated DNA should be considered in the
same manner. Genomic DNA is created by nature. While breaking off a
small segment may impart some new utility, it does not change the fact
that nature created that segment. Therefore, Judge Bryson found DNA
sequences isolated from genomic DNA unpatentable. 66
61

Id. at 1375-77 (explaining that diamonds and lithium are not patentable, man-made
inventions merely because they involve the breaking of chemical bonds).

62

Topoisomerases, a type of enzyme, introduce nicks or double strand breaks into DNA
to relieve supercoiling caused by DNA replication. ROBERT F. WEAVER, MOLECULAR
BIOLOGY 658 (4th ed. 2008).
63

See Myriad II, 653 F.3d at 1376 (Bryson, J., dissenting).

64

Id. at 1377.

65

See id.

66

Id. at 1375.
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IV. THE EFFECT OF MAYO V. PROMETHEUS LABORATORIES
[14] In light of the recent decision Mayo Collaborative Services v.
Prometheus Laboratories, Inc., the Federal Circuit was directed to
reconsider its earlier decision that isolated human DNA is patentable. 67
While the Mayo decision related specifically to the patentability of
processes claiming laws of nature, the Court’s reasoning provides
significant insight on analyzing patentability decisions directly implicating
the laws of nature and § 101. 68 The Court’s rejection of insignificant or
inconsequential steps following the direct application of a law of nature
further bolsters the notion that a substantial human innovative contribution
is required for patentability. 69
[15] Writing for the unanimous Court, Justice Breyer found
Prometheus’ patents claimed unpatentable subject matter. 70 The patents at
issue claim methods for “optimizing [the] therapeutic efficacy” of treating
certain autoimmune diseases. 71 The claimed methods sought to recapture
the correlation between the amount of a drug administered and the
resulting physiological effect. 72 The Court held this relationship alone

67

Ass’n for Molecular Pathology v. Myriad Genetics, No. 11-725, 2012 WL 986819, at
*1 (Mar. 26, 2012) (vacating the judgment and remanding to the Federal Circuit for
reconsideration).
68

See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1294
(2012).

69

See id. at 1297.

70

Id. at 1305.

71

Id. at 1295 (quoting U.S. Patent No. 6,355,623 (filed Apr. 8, 1999)).

72

Id. at 1296.
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was a law of nature and therefore not patentable. 73 In an attempt to
circumvent a § 101 rejection, the claimed processes were drafted to
include a transformative step to go beyond the law of nature. 74 While
these superfluous steps would likely avoid § 101 rejection under Bilski’s
“machine or transformation test,” the Court found they “add[] nothing to
the laws of nature that is not already present.” 75 Thus, the Court held the
addition of these “well-understood, routine, conventional” steps did not
bestow patentability upon the law of nature. 76
[16] In announcing this opinion, the Court reiterated a basic patent
principle: patents should promote scientific innovation. 77 Thus, when
examining patents involving the laws of nature, the scope of the claims
should not be so broad as to “improperly t[ie] up the future use of the laws
of nature.” 78 To restrain further research into that law of nature would
monopolize one of the “the basic tools of scientific and technological
work”directly contradicting a fundamental goal of patent law. 79
[17] When the Federal Circuit reconsiders the patent eligibility of
Myriad’s isolated DNA claims, it should be cognizant of the similarities

73

Mayo Collaborative Servs., 132 S. Ct. at 1297.

74

Id.

75

Id. at 1298.

76

Id.

77

See id. at 1301; see also U.S. CONST. art. 1, § 8, cl. 8 (“To promote the Progress of
Science and useful Arts, by securing for limited Times to Authors and Inventors the
exclusive Right to their respective Writings and Discoveries.”).
78

Mayo Collaborative Servs., 132 S. Ct. at 1301.

79

Id.
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between Prometheus’ and Myriad’s patents; each involves a law of nature
followed by a superfluous step. Just as the correlation between the
quantity and effect of a drug is a law of nature, so too is a human gene. 80
Therefore, the added step of ‘isolating’ the whole gene from the
chromosomal DNA should be analyzed like the “administering,”
“wherein,” and “determining” steps of the Prometheus patents.
[18] The step of ‘isolating’ DNA does not add sufficient novel subject
matter to the inherent law of nature to enable patenting. In order to
transform a law of nature into patentable subject matter, the subsequent
steps must be more than conventional, obvious, routine, or insignificant.81
Like the “determining” and “wherein” steps of the Prometheus patent, the
isolation of genomic DNA does nothing to change the law of nature
embodied by the isolated gene. 82 Rather, it is a universally known tool in
molecular biology: exactly the type of “well understood, routine,
conventional activity” already engaged in by the scientific community that
was insufficient to transform patent eligibility in Prometheus. 83 The
claims directed towards isolated BRCA1 and BRCA2 genes do nothing
more than attempt to monopolize the market in a law of nature embodied
as the genes. Therefore, the claims towards isolated DNA should be held
not patentable subject matter.
V. ARE GENES PATENTABLE SUBJECT MATTER?
80

See id. at 1296.

81

Id. at 1298.

82

See infra Part V.A.

83

Dennis Crouch, Mayo v. Prometheus: Natural Process + Known Elements = Normally
No Patent, PATENTLYO (Mar. 20, 2012),
http://www.patentlyo.com/patent/2012/03/mayo-v-prometheus-natural-process-knownelements-normally-no-patent.html.
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[18] Human genes, embodied as isolated DNA, are not patent-eligible
subject matter. As the Supreme Court recently vacated the Federal
Circuit’s original Myriad ruling, they are again tasked with deciding
whether isolated human DNA is patentable subject matter. 84 The majority
in the first Myriad decision incorrectly relied solely upon a chemical
perspectiveconsidering changes to DNA’s structurewhen analyzing
the differences between native and isolated DNA. 85 When examining the
patent eligibility of DNA, the Federal Circuit should examine both its
information and structure.
The chemical perspective ignores the
significance of the information content of DNA and, specifically, a gene.
From a biological perspective, a piece of isolated DNA is identical to
native DNA and, thus, fails the markedly different standard advanced by
the court. 86 When rehearing the issue on remand, the Federal Circuit
should consider all aspects of DNA, both structure and information, when
examining the eligibility of biological molecules.
A. The Informational Significance of DNA
[19] DNA is the blueprint of life. 87 The information contained in DNA
enables the creation of an entire human being. 88 The DNA molecule itself

84

Ass’n for Molecular Pathology v. Myriad Genetics, No. 11-725, 2012 WL 986819, at
*1 (Mar. 26, 2012).
85

See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329,
1351-53 (Fed. Cir. 2011).
86

See, e.g., Myriad I, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010).

87

Robert Aronson & Jacqueline McMurtie, The Use and Misuse of High-Tech Evidence
by Prosecutors: Ethical and Evidentiary Issues, 76 FORDHAM L. REV. 1453, 1469 (2007).
88

See WEAVER, supra note 62, at 32.
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is not incredibly complex; it is composed of a series of nucleosides 89
joined in a chain by a phosphate group. 90 Each nucleoside contains a
deoxyribose sugar and one of four nitrogenous bases: adenine (“A”),
thymine (“T”), cytosine (“C”), or guanine (“G”). 91 Thus, the structure of
DNA is composed of no more than repeating nucleotide segments of a
nitrogenous base, the deoxyribose sugar, and the phosphate group
arranged in a right-handed double helix.92 DNA molecules exist in the
nucleus double stranded, or hydrogen bonded to a complementary piece of
DNA, and wound around histone proteins in the chromatin. 93 The
histone’s function is to package the large volume of DNA so that it can fit
within the nucleus. 94 It simply binds the exterior of the DNA molecule
and does not modify the DNA or its structure in any material way. 95
[20] While this structure is important to DNA’s function, it is the
information contained in the nucleotide sequencethe order of the A, T,
89

Nucleosides and nucleotides are different entities. A nucleotide contains a nucleoside
as well as the phosphate group. Id. at 16-17. For the purposes of this comment, both are
the functional equivalent.
90

J.D. Watson & F.H.C. Crick, Molecular Structure of Nucleic Acids, 171 NATURE 737,
737-38 (1953).
91

Id.

92

Id.

93

WEAVER, supra note 62, at 23; Tony Kouzarides, Chromatin Modifications and Their
Function, 128 CELL 693, 693 (2007).
94

Kouzarides, supra note 93, at 693.

95

WEAVER, supra note 62, at 40-41 (explaining how DNA fits into the grooves on the
surface of the histone octamer and is only held in place through interactions with the
histone tails).
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C, and Gsthat makes DNA invaluable to an organism. 96 When an
organism activates a gene, it reads and copies the nucleotide sequence in
the process of transcription and then uses the copied sequence to produce a
protein during translation. 97 During transcription, the cell’s machinery
synthesizes a copy of the activated gene out of RNA. 98 Then, the structure
of the RNA is modified, including the removal of introns, to create
mRNA. 99 During translation, three base segments, known as codons, of
the mRNA are ‘read’ such that a specific amino acid is incorporated into
the nascent protein based on the sequence of the nucleotides within that
codon. 100 The protein is then incorporated into one of millions of
processes of the organism. Thus, by providing the blueprint for the
creation of cellular proteins, the information contained in DNA is an
important property that cannot be ignored.
[21] It is important to note that transcription does not occur while the
gene exists in its double stranded form as it would around histones. In
order for the gene to be activated for transcription, the histone proteins are
stripped away by the cell’s machinery and the DNA strands are separated
in what is known as the “transcription bubble.” 101 Thus, when the actual
informational content of the DNA is being accessed, the gene exists in a
markedly similar state to that of isolated DNAsingle stranded and
unbound to proteins.
96

Id. at 32 (explaining how the DNA sequence informs the creation of a protein).

97

See id. at 40-46.

98

WEAVER, supra note 62, at 40-41.

99

Id. at 401.

100

Id. at 44-46.

101

Id. at 41, 369-71.
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B. The Chemical Versus Biological Perspective
[22] When examining the patent eligibility of human genes, there are
two possible ways the subject matter can be examinedfrom a chemical
or biological perspective. The chemical perspective can be characterized
by looking strictly at the structure of the molecules composing DNA. 102 It
looks solely at the molecular structure of DNA, the layout of the
nucleotides and backbone, as well as any subsequent modification by
humans. Adopting this perspective, Judge Lourie, writing for the
majority, concluded that simply breaking the DNA backbone and the
unzipping of the double stranded structure amounted to a "markedly
different" change from the genomic DNA. 103 Examining the structure
without regard to the information content it holds ignores a fundamental
property of DNA.
[23] On the other hand, the biological perspective examines the
information content of the gene. It looks not at the structure but at the
information that structure reveals. DNA is known as the 'blueprint of life'
because it contains information that dictates the creation of an entire
organism. 104 While the structure does play a minor role in determining
this information content, it is the genetic sequence, or order of the
nucleotides within each gene, that contains the information. 105 By simply
102
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modifying the structure of the chromosome, i.e., excising a whole gene, no
change is made to the information content of each gene. 106 The
unchanged genetic sequence and information content in the isolated DNA
would fail the "markedly different" standard when compared to the
sequence and information contained in the genomic DNA.
[24] To exemplify this dichotomy between structure and information,
consider an analogy from copyright law. Consider a book. A book is
copyrightable with regard to the author’s exact portrayal of the
information it contains. 107 This is due in part to the fact that the societal
value of the book is not in its structureits number of pages, type of
cover, or method of binding. Rather, the author’s original portrayal of the
information in the book is what makes the book useful and deserving of a
copyright. 108 Thus, if a person copies a chapter of that book, she is an
infringer. 109 This infringer did not modify that chapter in any way. She
simply removed a piece of what already existed in the book and attempted
to pass it off as her own. While the chapter has a “markedly different”
structure than the whole book, the portrayal of the information contained
in the chapter is identical to what previously existed in the book. The
presence of that exact portrayal prevents the infringer from getting a new
copyright even though the structure of the book is different because the
significance of the book is not in its structure but in its content. 110
[25] The same result should be obtained in patent law, where genomic
DNA is the book and isolated DNA is the chapter. Native DNA, like a
106
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book composed of many chapters, is a unitary collection of many genes in
a single strand of DNA. 111 Likewise, isolated DNA is a chapter; the
largest pieces of isolated DNA contain at most a single gene. 112 As
previously noted, the significance of DNA, both to the human body and
for commercial exploitation, is mainly in its informational content, not its
physical structure. 113 Examining DNA’s patent eligibility solely based on
its structural differences is the functional equivalent of granting copyrights
on books based on the physical structure of the text. When examined in
this informational context, the information contained in the isolated DNA
is not "markedly different" from the relevant portion of the genomic DNA,
just as the information's portrayal in the chapter is not "markedly
different" from the information's portrayal in the entire book. Indeed, they
are exactly the same. Thus, just as one could not obtain a copyright for
simply removing the chapter of a book, one cannot obtain a patent for
simply isolating a specific sequence of DNA containing a gene.
C. Isolated DNA is not Patentable Subject Matter
[26] When determining whether a piece of DNA is patent eligible
subject matter, the court should take a totality-of-the-circumstances
approach, examining both the structure and information of the DNA.
111
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While both the District Court for the Southern District of New York and
the Federal Circuit deemed these approaches mutually exclusive, the
Supreme Court historically rejected the rigid application of a single test
when deciding issues of patentability. 114 In KSR International v. Teleflex
Inc., the Court rejected the exclusive application of the “teaching,
suggestion, or motivation test” when determining issues of obviousness
under § 103. 115 Similarly, in Bilski v. Kappos, the Supreme Court held
when determining patentability of processes under § 101, the “machine-ortransformation test” was not the sole test for patentability. 116 While just a
microcosm of the Court’s decisions, these cases demonstrate the Court’s
proclivity for denying the application of narrow rules in patent law. This
sort of narrow application is precisely the analysis the lower courts
performed when the district court looked solely at information and the
Federal Circuit looked solely at structure. 117 By considering both the
structure and the information content, neither the immense biological
significance of the nucleotide sequence nor the significance of structural
modifications is discounted.
[27] Applying the “markedly different” standard in this fashion reveals
isolated genomic DNA is not sufficiently different from genomic DNA to
be the subject of patent protection. Examining both from biological and
chemical perspectives reveal that the information contained in the isolated
DNA, and the vast majority of its structure, is identical to that of genomic
DNA. While there are four covalent bonds cleaved in the creation of
114
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isolated DNA, this minor structural change is insufficient to outweigh the
near identity of the two molecules to be considered “markedly different.”
i. Information Content is Identical
[28] Examining the information contained in the isolated DNA, it is not
“markedly different” from the information contained in the genomic DNA.
DNA contains information in its nucleotide sequence; the sequence
dictates the creation of a specific protein. 118 Thus, for the information
content to be markedly different, the isolated DNA sequence must code
for a protein sufficiently different from that found in nature.
[29] Because of the nature of isolated genomic DNA, the protein
resulting from transcription of the gene is identical to that resulting from
transcription of native DNA. Isolated DNA is produced by removing a
specific genomic DNA sequence, usually an entire gene, from the rest of
the cellular components. 119 The piece of DNA ‘isolated’ was actually
created by nature, with the exact same sequence, introns, and
promoters. 120 Therefore, with sequence identity to the native DNA, the
isolated DNA contains the same information as found in the native gene.
[30] This is exemplified by the ‘282 Patent where Claim 1 covers all
isolated DNAs that encode for the BRCA1 protein. 121 While the claim
does not specify a sequence, the specification discloses the nucleotide
118
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sequence of BRCA1 exactly as it is found in native DNA. 122 The
information contained the isolated DNA was not created by the ingenuity
of man, rather it is the product of millions of years of evolution, devoid of
any human input. Therefore, the information contained in the isolated
BRCA1 DNA is not “markedly different” from its genomic counterpart,
and thus under Chakrabarty, the isolated DNA is not patent eligible
subject matter.
ii. Structure is Insignificantly Different
[31] Aside from looking at the DNA’s information content, significant
structural changes to the DNA could render it patentable subject matter.
For instance, the synthesis of synthetic DNA, such as cDNA, has such a
different structure from what is found in nature that it is rendered
patentable. Yet, the process of isolating genomic DNA in no way creates
a “new . . . composition of matter” required by § 101. In fact, the isolated
DNA contains the exact same nucleotides, in the exact same sequence, as
existed in the genomic DNA in vivo. 123 The process of isolation is
described as the “remov[al] from its naturally occurring
environment.” 124 Thus, modification of the sequence is not
performed. Isolation simply removes what had already existed in the cell.
[32] This is exemplified by the claims of the ‘282 patent. Claim 1
covers an isolated DNA coding for the BRCA1 protein. 125 As the claims
of the patent are read in light of the specification, the claimed isolated
DNA would be composed of a portion of the genomic DNA, removed
122
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from the cellular proteins, coding for BRCA1. The isolated piece of
genomic DNA is disclosed to be 24,026 base pairs long, including the
promoter and introns. 126 The disclosed sequence even includes several
regions where the sequence is unknown, designated by repeating ‘v’s in
the patent. 127 Accordingly, the structure of the claimed isolated DNA and
the genomic DNA are identical.
[33] While the main structure of the DNA is identical, there is one
minor difference. Four covalent bonds have been cleaved that held the
segment-to-be-isolated into the DNA backbone. 128 The cleaving of these
four bonds, according to Judge Lourie, creates a “markedly different”
molecule. 129 But, examining the roots of the markedly different standard,
this is the wrong conclusion. The markedly different standard adopted by
the Federal Circuit comes from the Supreme Court’s holdings in
Chakrabarty and Hartranft. 130 This standard originated in Hartranft to
determine whether a seashell had undergone sufficient physical change to
be converted from a natural object to a manufacture. 131 The Court held
that even the etching away of layers of shell via acid was not sufficient to
fulfill the markedly different standard, because at its root, the shell was
still a shell. 132 In the case of isolated DNA, the breaking of four bonds, in
126
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light of the hundreds of thousands of bonds present in the entire molecule,
is insignificant. It is certainly a less extensive change than the acid
removal of entire layers of shell in Hartranft. Therefore, the breaking of
these bonds cannot be considered to create a “markedly different” DNA
molecule.
D. cDNA is Patentable Subject Matter
[34] The significant structural changes to the cDNA molecule outweigh
the informational identity thus permitting its patenting under § 101.
cDNA is a form of artificial DNA that is synthesized according to the
mature mRNA transcript of a gene. 133 The mature mRNA has undergone
significant changes following transcription, most notably the excision of
the introns, which can remove thousands of nucleotides. 134 For example,
the BRCA1 gene is shortened from 80,000 nucleotides in genomic form to
just 7,000 nucleotides in the mRNA as a result of splicing. 135 Scientists
then take this mRNA, using reverse transcriptase, create a synthetic DNA
molecule composed only of the coding exons that is found nowhere in
nature. 136
[35] Under the totality of the circumstances approach, cDNA is
patentable subject matter. While cDNA codes for the exact same protein
133
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as it is found in humans, the magnitude of the structural changes to the
gene itself as well as its synthetic nature make it markedly different from
anything found in a human. As noted before, the significance in DNA’s
information content requires significant structural modification to a native
sequence to permit patenting. 137 Unlike isolated DNA, which is derived
from natural, genomic DNA, cDNA is synthesized by man in a test
tube. 138 It requires the specific isolation of the target mRNA intending to
be replicated as well as the hybridization of a polythiamine primer to the
polyadenine tail to foster the binding of the synthesis enzyme. 139 The
result is a molecule of DNA that exists with no introns, unlike the
corresponding DNA sequence in the body. 140 The combination of its
synthetic nature and modified sequence amounts to sufficient changes to
the cDNA’s structure to overcome the information identity and make it
patent-eligible subject matter.
VI. CONCLUSION
[36] Mired in the complexities of eukaryotic genetics, the
straightforward question of whether human genes are patentable is easily
lost. The significance of each element of DNA has led each legal mind to
consider this issue to conclude differently. The district court and Federal
Circuit’s dissent champion the supremacy of DNA’s information content.
The majority and concurrence in the Federal Circuit supports the structural
changes. But, ignoring either the structure or the information undermines
the importance of these fundamental properties. Through a totality-of-thecircumstances approach, both information and structure are weighed in
order to determine whether the molecule as a whole is “markedly
137
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different” from genomic DNA, not just whether one property differs.
Under this analysis, isolated genomic DNA is not patentable subject
matter because of the structural changes undergone are relatively
insignificant in light of the molecules identical information content, and
cDNA is patentable subject matter because of the drastic, man-made
manipulations of the molecule’s structure.
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